TY - JOUR
AR - JSO-2020-3-108
TI - Clinical Experience with the Use of Neoadjuvant Hormone Therapy for Breast Cancer in a Latin American Cancer Center
AU - Ana María , Osorio
AU - Carlos , Lehmann
AU - Carlos , Duarte
AU - Javier , Angel
AU - Luis , Guzman
AU - Marcela , Nuñez-Lemus
AU - Martha Cecilia , Orozco
AU - Mauricio , García
AU - Ricardo , Sánchez
AU - Sandra, Díaz
AU - Sara , Mendoza
AU - Sergio , Cervera
AU - Wilmar , Serrano
JO - Journal of Surgical Oncology
PY - 2020
DA - Fri 29, May 2020
SN - 2674-3000
DO - http://dx.doi.org/10.31487/j.JSO.2020.03.08
UR - https://www.sciencerepository.org/clinical-experience-with-the-use-of-neoadjuvant-hormone-therapy-for_JSO-2020-3-108 
KW - Breast neoplasms, aromatase inhibitors, tamoxifen, estrogen receptors, segmental mastectomy
AB - Introduction: The most frequent subtype of breast cancer is the luminal one, in 70 to 80% of cases; the
poor response to neoadjuvant chemotherapy of these tumors positions neoadjuvant hormone therapy as a
treatment option.
Materials and Methods: An observational, descriptive, historical cohort study was conducted in patients
with hormone receptor (HR positive and HER2-positive breast cancer, managed with neoadjuvant hormone
therapy in the INC (National Cancer Institute, for its initials in Spanish), with the aim of evaluating their
clinical and pathological response.
Results: 57 patients were managed with neoadjuvant hormone therapy. Most stage IIA patients (40.3%, n
= 23). 86% (n = 49) had luminal A tumors. Letrozole was the most widely used drug, in 78.9% (n = 45).
The overall response rate (ORR) was reached in 94.6% (n = 53); and 10.7% of the patients (n = 6) achieved
complete clinical response (cCR). Complete pathological response (pCR) was achieved only in one patient.
Conservative surgery was possible in 56.9% (n = 29) of the patients. There was no difference between the
type of aromatase inhibitor (AI) and the duration of neoadjuvant hormonal treatment with the clinical
response. With a median follow-up of 3 years (0.6 and 6 years), no disease progression was reported in any
of the patients in the study.
Conclusion: The results of this study support the neoadjuvant hormone therapy recommendations for
postmenopausal patients older than 65 years with luminal breast cancer, with well or moderately
differentiated tumors, strongly HR positive and low Ki 67.